var data={"title":"Drug eruptions","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Drug eruptions</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/drug-eruptions/contributors\" class=\"contributor contributor_credentials\">Andrew D Samel, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/drug-eruptions/contributors\" class=\"contributor contributor_credentials\">Chia-Yu Chu, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/drug-eruptions/contributors\" class=\"contributor contributor_credentials\">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/drug-eruptions/contributors\" class=\"contributor contributor_credentials\">Maja Mockenhaupt, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/drug-eruptions/contributors\" class=\"contributor contributor_credentials\">Jean-Claude Roujeau, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/drug-eruptions/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/drug-eruptions/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 03, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adverse cutaneous reactions to drugs are common, affecting 2 to 3 percent of hospitalized patients, and are a significant cause of outpatient morbidity [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/1\" class=\"abstract_t\">1</a>]. It is estimated that 1 in 1000 hospitalized patients has a serious cutaneous drug reaction. </p><p>Classic and uncommon cutaneous drug reactions will be reviewed here. Drug allergy, hypersensitivity reactions, and infusion reactions and cutaneous complications of antineoplastic drugs are discussed elsewhere. </p><p>(See <a href=\"topic.htm?path=drug-allergy-classification-and-clinical-features\" class=\"medical medical_review\">&quot;Drug allergy: Classification and clinical features&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=hypersensitivity-reactions-to-macrolides-aminoglycosides-tetracyclines-clindamycin-and-metronidazole\" class=\"medical medical_review\">&quot;Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=hypersensitivity-reactions-to-fluoroquinolones\" class=\"medical medical_review\">&quot;Hypersensitivity reactions to fluoroquinolones&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=hypersensitivity-reactions-to-clopidogrel\" class=\"medical medical_review\">&quot;Hypersensitivity reactions to clopidogrel&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=vancomycin-hypersensitivity\" class=\"medical medical_review\">&quot;Vancomycin hypersensitivity&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=progestogen-hypersensitivity\" class=\"medical medical_review\">&quot;Progestogen hypersensitivity&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=hypersensitivity-reactions-to-systemic-glucocorticoids\" class=\"medical medical_review\">&quot;Hypersensitivity reactions to systemic glucocorticoids&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=hypersensitivity-reactions-to-insulins\" class=\"medical medical_review\">&quot;Hypersensitivity reactions to insulins&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=infusion-reactions-to-systemic-chemotherapy\" class=\"medical medical_review\">&quot;Infusion reactions to systemic chemotherapy&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=infusion-related-reactions-to-therapeutic-monoclonal-antibodies-used-for-cancer-therapy\" class=\"medical medical_review\">&quot;Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents\" class=\"medical medical_review\">&quot;Cutaneous side effects of conventional chemotherapy agents&quot;</a>.)</p><p>(See <a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">&quot;Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLASSIC DRUG REACTION PATTERNS</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Drug-induced exanthems</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drug-induced exanthems are the most common cutaneous reactions to drugs, responsible for approximately 90 percent of all drug rashes [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/2\" class=\"abstract_t\">2</a>]. The most commonly prescribed medications (eg, antibiotics, sulfonamides) are implicated in most cases. The rashes are referred to as exanthems, morbilliform (<a href=\"image.htm?imageKey=DERM%2F54205%7EALLRG%2F70062\" class=\"graphic graphic_picture graphicRef54205 graphicRef70062 \">picture 1A-B</a>), and macular and papular eruptions [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/3\" class=\"abstract_t\">3</a>]. The clinical features, diagnosis and management of exanthematous drug eruptions are discussed in detail separately. (See <a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption\" class=\"medical medical_review\">&quot;Exanthematous (maculopapular) drug eruption&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H79787039\"><span class=\"h3\">Symmetrical drug-related intertriginous and flexural exanthema</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE, intertriginous drug eruption, baboon syndrome) is an infrequent type of drug-induced rash. SDRIFE occurs a few hours to a few days after the administration of the offending drug. The rash presents as a sharply demarcated V-shaped erythema in the <span class=\"nowrap\">gluteal/perianal</span> or <span class=\"nowrap\">inguinal/perigenital</span> areas, often with involvement of at least one other flexural or intertriginous fold, in the absence of systemic symptoms [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/4\" class=\"abstract_t\">4</a>]. <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">Amoxicillin</a>, <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a>, penicillin, <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>, and <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a> are thought to be implied in about 50 percent of cases [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/4\" class=\"abstract_t\">4</a>]. Iodinate contrast media, <a href=\"topic.htm?path=pseudoephedrine-drug-information\" class=\"drug drug_general\">pseudoephedrine</a>, acetyl salicylic acid, <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a> C, phenothiazines, <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>, and many other drugs have also been implicated [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/5\" class=\"abstract_t\">5</a>]. Treatment includes discontinuing the suspected drug and the use of topical or systemic corticosteroids. (See <a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption#H1366656\" class=\"medical medical_review\">&quot;Exanthematous (maculopapular) drug eruption&quot;, section on 'Intertriginous and flexural localization'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Urticaria/angioedema</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Urticaria, or hives, is characterized by an intensely pruritic, circumscribed, raised, and erythematous eruption with central pallor (<a href=\"image.htm?imageKey=PC%2F72519\" class=\"graphic graphic_picture graphicRef72519 \">picture 2</a>). Individual lesions may enlarge, coalesce with other lesions, and typically disappear over a few hours. Urticaria is mediated by the cutaneous mast cell in the superficial dermis. (See <a href=\"topic.htm?path=new-onset-urticaria\" class=\"medical medical_review\">&quot;New-onset urticaria&quot;</a>.)</p><p>Angioedema is swelling of the deeper dermis and subcutaneous tissues that may coexist with urticaria in as many as 50 percent of cases. Angioedema may be disfiguring if it involves the face and lips, or life-threatening if airway obstruction occurs from laryngeal edema or tongue swelling. Angioedema can result from mast cell activation in the subcutaneous tissues, or by non-mast cell-mediated mechanisms. These mechanisms include abnormalities of the complement cascade (inherited and acquired abnormalities of complement metabolism), and increased activity of vasodilatory kinin pathways. Angioedema (in the absence of urticaria) occurs in 2 to 10 per 10,000 new users of ACE inhibitors and usually affects the mouth or tongue. (See <a href=\"topic.htm?path=an-overview-of-angioedema-pathogenesis-and-causes\" class=\"medical medical_review\">&quot;An overview of angioedema: Pathogenesis and causes&quot;</a>.)</p><p>Reactions involving <span class=\"nowrap\">urticaria/angioedema</span> can be immediate, accelerated (hours post-exposure) or delayed (days post-exposure). As with most drug eruptions, these reactions are more common during the first weeks of therapy, but can happen at any time.</p><p>Urticaria <span class=\"nowrap\">and/or</span> angioedema may be manifestations of an IgE-mediated (type I hypersensitivity) drug reaction (<a href=\"image.htm?imageKey=PULM%2F71375\" class=\"graphic graphic_table graphicRef71375 \">table 1</a>). Antibiotics (especially penicillins, cephalosporins, and sulfonamides) are common causes of IgE-mediated drug allergy. IgE-mediated drug reactions tend to become more severe and progress toward anaphylaxis upon re-exposure to the causative agent. (See <a href=\"topic.htm?path=penicillin-allergy-immediate-reactions\" class=\"medical medical_review\">&quot;Penicillin allergy: Immediate reactions&quot;</a>.)</p><p>Other drugs may cause urticaria due to mast cell degranulation by a non-IgE mediated mechanism. The most frequently implicated are the opiate analgesics <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> and <a href=\"topic.htm?path=codeine-drug-information\" class=\"drug drug_general\">codeine</a>. The concomitant use of opiates and <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> may increase the frequency of reactions to the latter. The intense flushing of &quot;Red man syndrome&quot; seen after rapid vancomycin infusion also is due to direct mast cell activation and may have accompanying urticaria. (See <a href=\"topic.htm?path=vancomycin-hypersensitivity\" class=\"medical medical_review\">&quot;Vancomycin hypersensitivity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Anaphylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most severe form of immediate type I hypersensitivity is anaphylaxis, which is characterized by symptoms affecting multiple organ systems, including but not limited to pruritus, urticaria, angioedema, laryngeal edema, wheezing, nausea, vomiting, tachycardia, sense of impending doom, and occasionally shock. Drugs are the second or third most common cause of anaphylaxis [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/6,7\" class=\"abstract_t\">6,7</a>]. (See <a href=\"topic.htm?path=anaphylaxis-emergency-treatment\" class=\"medical medical_review\">&quot;Anaphylaxis: Emergency treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Cutaneous small vessel vasculitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cutaneous small vessel vasculitis (CSVV, also called hypersensitivity vasculitis, cutaneous leukocytoclastic vasculitis, serum sickness or serum sickness-like reactions, and allergic vasculitis) is a single organ vasculitis caused in most cases by drugs [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/8-10\" class=\"abstract_t\">8-10</a>]. <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">Hydralazine</a>, <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a>, <a href=\"topic.htm?path=propylthiouracil-drug-information\" class=\"drug drug_general\">propylthiouracil</a>, and levamisole-adulterated cocaine are most often reported as causes of CSVV [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/11\" class=\"abstract_t\">11</a>]; penicillins, cephalosporins, sulfonamides (including most loop and thiazide-type diuretics), <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, and <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a> have also been implicated (<a href=\"image.htm?imageKey=RHEUM%2F81148\" class=\"graphic graphic_table graphicRef81148 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/12-15\" class=\"abstract_t\">12-15</a>].</p><p>CSVV typically presents with palpable purpura <span class=\"nowrap\">and/or</span> petechiae (<a href=\"image.htm?imageKey=DERM%2F58626%7EDERM%2F93176\" class=\"graphic graphic_picture graphicRef58626 graphicRef93176 \">picture 3A-B</a>); additional clinical findings include fever, urticaria, arthralgias, lymphadenopathy, low serum complement levels, and an elevated erythrocyte sedimentation rate. In most patients, the clinical manifestations begin 7 to 10 days after exposure to the offending drug [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/12\" class=\"abstract_t\">12</a>]. However, the latent period may be as short as two to seven days with a secondary exposure or longer than two weeks with a long-acting drug such as <a href=\"topic.htm?path=penicillin-g-benzathine-long-acting-intramuscular-drug-information\" class=\"drug drug_general\">penicillin G benzathine</a> [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/13\" class=\"abstract_t\">13</a>].</p><p>Discontinuation of the offending drug should lead to resolution of the signs and symptoms within a period of days to a few weeks. Patients with more severe reactions may require nonsteroidal anti-inflammatory drugs or corticosteroids. (See <a href=\"topic.htm?path=overview-of-cutaneous-small-vessel-vasculitis\" class=\"medical medical_review\">&quot;Overview of cutaneous small vessel vasculitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Exfoliative dermatitis/erythroderma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythroderma is a cutaneous reactional state defined as chronic erythema and scale involving greater than 90 percent of the body surface area (<a href=\"image.htm?imageKey=DERM%2F93175\" class=\"graphic graphic_picture graphicRef93175 \">picture 4</a>). Common etiologies include drugs, primary skin disease (eg, atopic dermatitis, psoriasis), and malignancy (especially lymphoreticular malignancy and cutaneous T cell lymphoma). (See <a href=\"topic.htm?path=erythroderma-in-adults\" class=\"medical medical_review\">&quot;Erythroderma in adults&quot;</a>.)</p><p>Drugs are responsible for approximately 20 percent of erythrodermas; implicated drugs include <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a>, penicillins, barbiturates, gold salts, arsenic, and mercury (<a href=\"image.htm?imageKey=PC%2F62321\" class=\"graphic graphic_picture graphicRef62321 \">picture 5</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/1\" class=\"abstract_t\">1</a>]. In some patients, exfoliative dermatitis may be a manifestation of drug reaction with eosinophilia and systemic symptoms (DRESS). (See <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p>This disorder is associated with an increased rate of epidermal turnover, including rapid epidermal cell migration [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/16\" class=\"abstract_t\">16</a>]. This is presumably mediated by inflammatory cells and represents the most severe manifestation of many inflammatory dermatoses. The clinical manifestations, diagnosis, and management of erythroderma are discussed separately. (See <a href=\"topic.htm?path=erythroderma-in-adults\" class=\"medical medical_review\">&quot;Erythroderma in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4963591\"><span class=\"h2\">Stevens-Johnson syndrome and toxic epidermal necrolysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous eruptions that are frequently triggered by medications. These disorders are characterized by epidermal necrosis and sloughing of the mucous membranes and skin (<a href=\"image.htm?imageKey=EM%2F76141%7EEM%2F73805%7EDERM%2F59418%7EDERM%2F68458%7EDERM%2F82150\" class=\"graphic graphic_picture graphicRef76141 graphicRef73805 graphicRef59418 graphicRef68458 graphicRef82150 \">picture 6A-E</a>). The amount of body surface area involved is used to distinguish SJS from TEN; lesions affect less than 10 percent of the body surface in SJS and greater than 30 percent of the body surface in TEN. The clinical manifestations, diagnosis, and management of SJS and TEN are discussed elsewhere. (See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Erythema multiforme</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythema multiforme (EM) majus (or erythema multiforme major) is sometimes used as a synonym for SJS but is considered to be a different condition [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/1,17\" class=\"abstract_t\">1,17</a>]. It is an acute eruption characterized by distinctive target skin lesions. Lesions tend to affect the distal extremities, including the palms and soles (<a href=\"image.htm?imageKey=ID%2F74095\" class=\"graphic graphic_picture graphicRef74095 \">picture 7</a>). EM has diagnostic histology and is often caused by infections (typically herpes simplex virus or Mycoplasma pneumoniae) and has a benign clinical course [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/1\" class=\"abstract_t\">1</a>]. However, there are reports of EM in association with medication use [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/18,19\" class=\"abstract_t\">18,19</a>]. (See <a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-erythema-multiforme\" class=\"medical medical_review\">&quot;Pathogenesis, clinical features, and diagnosis of erythema multiforme&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drug reaction with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity syndrome (DIHS) is a severe idiosyncratic reaction characterized by fever (38 to 40&deg;C [100.4 to 104&deg;F]), malaise, lymphadenopathy, and skin eruption (<a href=\"image.htm?imageKey=DERM%2F86763%7EDERM%2F86859%7EDERM%2F86860\" class=\"graphic graphic_picture graphicRef86763 graphicRef86859 graphicRef86860 \">picture 8A-C</a>) [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/20\" class=\"abstract_t\">20</a>]. Additional systemic symptoms may be related to visceral involvement (eg, liver, kidney, lung) [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/21,22\" class=\"abstract_t\">21,22</a>]. In most patients, the reaction begins two to six weeks after the initiation of the offending medication. The aromatic antiepileptic agents (<a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, <a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">oxcarbazepine</a>, and <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>), <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a>, and the sulfonamides are the most frequent causes of this disorder (<a href=\"image.htm?imageKey=DERM%2F86760\" class=\"graphic graphic_table graphicRef86760 \">table 3</a>). The clinical presentation, diagnosis, and management of DRESS are discussed in detail separately. (See <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Fixed drug eruption</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A fixed drug eruption is a distinctive reaction characterized acutely by erythematous and edematous plaques with a grayish center or frank bullae, and chronically by a dark postinflammatory pigmentation (<a href=\"image.htm?imageKey=DERM%2F52192%7EDERM%2F65991\" class=\"graphic graphic_picture graphicRef52192 graphicRef65991 \">picture 9A-B</a>). Favored sites include the mouth (lips and tongue), genitalia, face, and acral areas [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/3\" class=\"abstract_t\">3</a>]. The defining features of this eruption include postinflammatory hyperpigmentation and recurrence of lesions at exactly the same sites with drug re-exposure [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/3\" class=\"abstract_t\">3</a>]. Patients with generalized fixed drug eruption (GFDG) can be misdiagnosed as having <span class=\"nowrap\">SJS/TEN,</span> but in GFDG mucosal involvement is usually absent or mild and the clinical course is favorable with rapid resolution in 7 to 14 days after drug discontinuation [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/23\" class=\"abstract_t\">23</a>]. The drugs commonly involved include NSAIDs (acetylsalicylic acid, <a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">ibuprofen</a>, <a href=\"topic.htm?path=naproxen-drug-information\" class=\"drug drug_general\">naproxen</a>, <a href=\"topic.htm?path=mefenamic-acid-drug-information\" class=\"drug drug_general\">mefenamic acid</a>), antibacterial agents (<a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, tetracyclines, penicillins, quinolones, <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a>), barbiturates, <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a> (paracetamol), and antimalarials [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/3,23-26\" class=\"abstract_t\">3,23-26</a>]. The clinical presentation, diagnosis, and management of fixed drug eruption are discussed in detail separately. (See <a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">&quot;Fixed drug eruption&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Photosensitivity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are two basic types of photo eruptions, phototoxic and photoallergic, which differ in clinical appearance and pathogenesis. (See <a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment#H22\" class=\"medical medical_review\">&quot;Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment&quot;, section on 'Phototoxicity'</a> and <a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment#H25\" class=\"medical medical_review\">&quot;Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment&quot;, section on 'Photoallergy'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Phototoxic eruptions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Phototoxic eruptions are by far the most common drug-induced photo eruptions. They are caused by absorption of ultraviolet light by the causative drug, which releases energy and damages cells. Ultraviolet A light (UVA) is the most common wavelength implicated; ultraviolet B light (UVB) and visible light can elicit reactions with some drugs.</p><p>The eruption typically presents as an exaggerated sunburn, often with blisters (<a href=\"image.htm?imageKey=DERM%2F86479\" class=\"graphic graphic_picture graphicRef86479 \">picture 10</a>). NSAIDs, quinolones, tetracyclines, <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>, and the phenothiazines are the most frequent causes of phototoxicity [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment#H22\" class=\"medical medical_review\">&quot;Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment&quot;, section on 'Phototoxicity'</a>.)</p><p>Molecularly targeted agents such as <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">vemurafenib</a> may also cause phototoxic reaction. (See <a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">&quot;Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Photoallergic eruptions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Photoallergy is a lymphocyte-mediated reaction caused by exposure to UVA. It is postulated that the absorbed radiation converts the drug into an immunologically active compound that is then presented to lymphocytes by Langerhans cells, causing a spongiotic dermatitis (eczema). The eruption is characterized by widespread eczema in the photodistribution: face; upper chest; and back of hands (<a href=\"image.htm?imageKey=DERM%2F63557\" class=\"graphic graphic_picture graphicRef63557 \">picture 11</a>).</p><p>Most photoallergic reactions are caused by topical agents including biocides added to soaps (halogenated phenolic compounds) and fragrances such as musk ambrette and 6-methyl coumarin [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/27\" class=\"abstract_t\">27</a>]. Systemic photoallergens such as the phenothiazines, <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a>, sulfa products, and NSAIDs can produce photoallergic reactions, although most of their photosensitive reactions are phototoxic [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment#H25\" class=\"medical medical_review\">&quot;Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment&quot;, section on 'Photoallergy'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">UNCOMMON DRUG ERUPTIONS</span></p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Pemphigus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pemphigus is an autoimmune bullous disease that may be drug-induced or drug-triggered (<a href=\"image.htm?imageKey=DERM%2F88293\" class=\"graphic graphic_table graphicRef88293 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/28\" class=\"abstract_t\">28</a>]. The latter term refers to unmasking of latent disease by a particular drug. The drugs most often implicated are <a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">penicillamine</a> and other thiol (SH) compounds, including <a href=\"topic.htm?path=captopril-drug-information\" class=\"drug drug_general\">captopril</a> or drugs such as <a href=\"topic.htm?path=piroxicam-drug-information\" class=\"drug drug_general\">piroxicam</a> that are metabolized to thiols [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/29\" class=\"abstract_t\">29</a>]; penicillin and its derivatives, but not cephalosporins, also have been implicated (<a href=\"image.htm?imageKey=DERM%2F88293\" class=\"graphic graphic_table graphicRef88293 \">table 4</a>). (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus#H118261971\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;, section on 'Drug exposure'</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Bullous pemphigoid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are isolated case reports of drug-induced bullous pemphigoid [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/30-33\" class=\"abstract_t\">30-33</a>]. <a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">Penicillamine</a> and <a href=\"topic.htm?path=furosemide-drug-information\" class=\"drug drug_general\">furosemide</a> are most frequently implicated, although cases associated with <a href=\"topic.htm?path=captopril-drug-information\" class=\"drug drug_general\">captopril</a>, penicillin and its derivatives, <a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">sulfasalazine</a>, salicylazosulfapyridine, phenacetin, nalidixic acid, and topical <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a> also have been reported (<a href=\"image.htm?imageKey=DERM%2F56085\" class=\"graphic graphic_table graphicRef56085 \">table 5</a>) [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/34-36\" class=\"abstract_t\">34-36</a>]. Case-control studies have found a significant association between bullous pemphigoid and neuroleptics, loop diuretics, and <a href=\"topic.htm?path=spironolactone-drug-information\" class=\"drug drug_general\">spironolactone</a> [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/37-39\" class=\"abstract_t\">37-39</a>].</p><p>Drug-induced bullous pemphigoid falls into two categories. It is either an acute, self-limited illness with resolution after drug withdrawal, or a chronic type that appears to be merely precipitated by drug administration and eventually assumes all the characteristics of the typical autoimmune disease [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/30\" class=\"abstract_t\">30</a>]. Clinical manifestations include tense vesicles and bullae on an inflammatory base distributed on the arms, legs, and trunk of older patients. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid#H590419\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid&quot;, section on 'Infections and drugs'</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Linear IgA bullous dermatosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Linear IgA bullous dermatosis is an idiopathic subepidermal blistering disease characterized histologically by the linear deposition of IgA antibodies at the basement membrane zone. A spectrum of clinical features has been described. Patients with drug-induced disease may have erythema multiforme-type lesions, bullous pemphigoid-like lesions, or dermatitis herpetiformis-like lesions [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/40\" class=\"abstract_t\">40</a>]. Mucosal or conjunctival lesions are not present in drug-induced disease but are common in the idiopathic form.</p><p><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> is most commonly implicated; <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, cefamandole, <a href=\"topic.htm?path=captopril-drug-information\" class=\"drug drug_general\">captopril</a>, and <a href=\"topic.htm?path=diclofenac-drug-information\" class=\"drug drug_general\">diclofenac</a> have also been associated with this illness. Spontaneous remission occurs in drug-induced disease once the offending agent is discontinued. (See <a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">&quot;Linear IgA bullous dermatosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Acute generalized exanthematous pustulosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute generalized exanthematous pustulosis (AGEP) is a rare disorder characterized by the appearance of superficial pustules after drug ingestion or infection [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/41,42\" class=\"abstract_t\">41,42</a>]. AGEP is remarkable for its short time to onset (24 hours) after the administration of the suspected drug, although in some cases, the onset of symptoms may be delayed for up to three weeks [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/43\" class=\"abstract_t\">43</a>].</p><p>The cutaneous eruption begins on the face or intertriginous areas and disseminates within a few hours. Nonfollicular small pustules arise on edematous erythema with burning <span class=\"nowrap\">and/or</span> itching (<a href=\"image.htm?imageKey=ALLRG%2F56807%7EALLRG%2F68610\" class=\"graphic graphic_picture graphicRef56807 graphicRef68610 \">picture 12A-B</a>). Antibiotics, particularly penicillins and macrolides, are thought to play a role in 80 percent of cases [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/42,44\" class=\"abstract_t\">42,44</a>]. The clinical manifestations, diagnosis, and management of AGEP are discussed separately. (See <a href=\"topic.htm?path=acute-generalized-exanthematous-pustulosis-agep\" class=\"medical medical_review\">&quot;Acute generalized exanthematous pustulosis (AGEP)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Lichenoid drug eruption (drug-induced lichen planus)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lichen planus is characterized by flat-topped, violaceous, pruritic papules (<a href=\"image.htm?imageKey=DERM%2F63590%7EDERM%2F80165%7EDERM%2F59258\" class=\"graphic graphic_picture graphicRef63590 graphicRef80165 graphicRef59258 \">picture 13A-C</a>). The drug-induced form of this disorder usually develops insidiously and can affect any area of the body surface. Oral lichenoid drug eruptions are rare and share clinical features with oral lichen planus. (See <a href=\"topic.htm?path=oral-lichen-planus-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Oral lichen planus: Pathogenesis, clinical features, and diagnosis&quot;</a>.)</p><p>Beta-blockers, <a href=\"topic.htm?path=methyldopa-drug-information\" class=\"drug drug_general\">methyldopa</a>, <a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">penicillamine</a>, <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a>, and NSAIDs may cause this disorder [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/45\" class=\"abstract_t\">45</a>]. Lichenoid drug eruption is discussed in detail separately. (See <a href=\"topic.htm?path=lichenoid-drug-eruption-drug-induced-lichen-planus\" class=\"medical medical_review\">&quot;Lichenoid drug eruption (drug-induced lichen planus)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Alopecia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drugs cause hair loss by two major mechanisms: inducing an abrupt cessation of mitotic activity in rapidly dividing hair matrix cells (anagen effluvium); or precipitating the follicles into premature rest (telogen effluvium). In the former, hair loss usually occurs within days to weeks of drug administration; in the latter, hair loss occurs two to four months after starting treatment. Anagen effluvium is seen most commonly with antineoplastic drugs. (See <a href=\"topic.htm?path=chemotherapy-induced-alopecia\" class=\"medical medical_review\">&quot;Chemotherapy-induced alopecia&quot;</a>.)</p><p>Telogen effluvium is seen in association with many drugs including anticoagulants, retinoids, interferons, and antihyperlipidemic drugs [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/46\" class=\"abstract_t\">46</a>]. (See <a href=\"topic.htm?path=telogen-effluvium\" class=\"medical medical_review\">&quot;Telogen effluvium&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Cutaneous pseudolymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anticonvulsants, antidepressants, antihypertensives, beta blockers, calcium channel blockers, diuretics, antibiotics, nonsteroidal anti-inflammatory drugs, antihistamines, and biologics have been linked with benign hyperplastic lymphoid infiltrates of the skin (cutaneous pseudolymphoma) [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/47-50\" class=\"abstract_t\">47-50</a>]. The lesions are often solitary or few in number and most often are nodular or plaque-like (<a href=\"image.htm?imageKey=DERM%2F103512\" class=\"graphic graphic_picture graphicRef103512 \">picture 14</a>). Various histologic variations are noted, including a mycosis fungoides-like pattern [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/51\" class=\"abstract_t\">51</a>]. In most patients, the skin lesions resolve when the offending drug is discontinued. (See <a href=\"topic.htm?path=cutaneous-t-cell-pseudolymphomas#H373512063\" class=\"medical medical_review\">&quot;Cutaneous T cell pseudolymphomas&quot;, section on 'Lymphomatoid drug reaction'</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Acral chemotherapy reactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acral erythema (also called hand-foot syndrome or palmar-plantar erythrodysesthesia) occurs most often in patients with cancer treated with cytosine arabinoside, <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>, <a href=\"topic.htm?path=capecitabine-drug-information\" class=\"drug drug_general\">capecitabine</a> (an oral 5-fluorouracil derivative), or <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>. (See <a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents#H23\" class=\"medical medical_review\">&quot;Cutaneous side effects of conventional chemotherapy agents&quot;, section on 'Hand-foot syndrome (acral erythema)'</a>.)</p><p>The small molecule tyrosine kinase inhibitors <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> and <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a> and others that target angiogenesis are also associated with a high incidence of hand-foot skin reaction, but the clinical and histologic patterns differ from the classic acral erythema caused by conventional cytotoxic agents. (See <a href=\"topic.htm?path=hand-foot-skin-reaction-induced-by-multitargeted-tyrosine-kinase-inhibitors\" class=\"medical medical_review\">&quot;Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors&quot;</a>.)</p><p>In both types of acral reactions, dysesthesia of the involved areas (eg, paresthesia, tingling, burning, painful sensation) precedes the development of the skin lesions. Acral erythema is most often characterized by a symmetric edema and erythema of the palms and soles, which may progress to blistering and necrosis (<a href=\"image.htm?imageKey=DERM%2F79857%7EONC%2F77501\" class=\"graphic graphic_picture graphicRef79857 graphicRef77501 \">picture 15A-B</a>). In contrast, hand-foot skin reaction is characterized by well demarcated, bean to coin sized, hyperkeratotic, painful plaques with underlying erythema localized to the pressure areas of the soles (<a href=\"image.htm?imageKey=ONC%2F81824\" class=\"graphic graphic_picture graphicRef81824 \">picture 16</a>) [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/52\" class=\"abstract_t\">52</a>]. </p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Drug-induced lupus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drug-induced lupus is similar to spontaneous lupus but also has some different clinical and immunologic features (<a href=\"image.htm?imageKey=RHEUM%2F69467\" class=\"graphic graphic_table graphicRef69467 \">table 6</a>). A variety of drugs can induce a lupus-like syndrome, particularly those agents that are metabolized by acetylation such as <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">procainamide</a> and <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">hydralazine</a> [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"topic.htm?path=drug-induced-lupus\" class=\"medical medical_review\">&quot;Drug-induced lupus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">DRUGS OF SPECIAL CONCERN</span></p><p class=\"headingAnchor\" id=\"H460534\"><span class=\"h2\">Anticoagulants</span></p><p class=\"headingAnchor\" id=\"H460547\"><span class=\"h3\">Warfarin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Warfarin-induced skin necrosis typically occurs during the first several days of <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> therapy, often in association with the administration of large loading doses [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/54\" class=\"abstract_t\">54</a>]. The skin lesions occur on the extremities, breasts, trunk, and penis (in males) and marginate over a period of hours from an initial central erythematous macule (<a href=\"image.htm?imageKey=HEME%2F80462\" class=\"graphic graphic_picture graphicRef80462 \">picture 17</a>). Biopsies demonstrate fibrin thrombi within cutaneous vessels with interstitial hemorrhage.</p><p>Skin necrosis appears to be mediated by the reduction in protein C levels on the first day of therapy, which induces a transient hypercoagulable state. Approximately one-third of patients have underlying protein C deficiency, although skin necrosis is an infrequent complication of <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> therapy among patients with protein C deficiency [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/55\" class=\"abstract_t\">55</a>]. Case reports have also described this syndrome in association with an acquired functional deficiency of protein C, heterozygous protein S deficiency, and factor V Leiden. (See <a href=\"topic.htm?path=protein-c-deficiency#H13\" class=\"medical medical_review\">&quot;Protein C deficiency&quot;, section on 'Warfarin-induced skin necrosis'</a>.)</p><p class=\"headingAnchor\" id=\"H460596\"><span class=\"h3\">Heparin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Heparin may induce several skin reactions including delayed-type hypersensitivity reactions and, rarely, immediate hypersensitivity reactions or skin necrosis [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/56\" class=\"abstract_t\">56</a>]. Delayed-type hypersensitivity reactions may occur with both unfractionated and low-molecular-weight heparins, generally within two weeks of heparin treatment. Delayed-type reactions present most often with localized erythema at the injection site, but may progress to generalized eczematous or maculopapular eruption. </p><p>Immediate hypersensitivity reactions are rare and manifest as anaphylactic (IgE mediated) or anaphylactoid (non-IgE mediated) reactions [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/57\" class=\"abstract_t\">57</a>]. Clinical symptoms include localized or generalized urticaria, hypotension, angioedema, allergic rhinoconjunctivitis, tachycardia, or bronchospasm.</p><p>Skin necrosis may develop in 10 to 20 percent of patients with heparin-induced immune-mediated thrombocytopenia, a rare and life-threatening complication of treatment with unfractionated or low molecular-weight heparins [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/58,59\" class=\"abstract_t\">58,59</a>]. Cutaneous necrosis is caused by intradermal microvascular thromboses occurring locally or distantly from the injection site. Lesions appear 3 to 15 days after the initiation of therapy as erythematous patches that progress to skin necrosis. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-heparin-induced-thrombocytopenia\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of heparin-induced thrombocytopenia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h2\">Gold</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dermatitis and stomatitis account for most adverse gold reactions. Gold rashes are highly variable and may mimic many other skin conditions. In a prospective study of 74 patients with rheumatoid arthritis, 39 patients developed a mucocutaneous reaction to gold [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/60\" class=\"abstract_t\">60</a>]. A variety of morphologic features were noted, the bulk of which were characterized as nonspecific dermatitis (six of these patients had an associated stomatitis, six had a dyshidrotic eczema presentation). In three patients the reaction resembled contact dermatitis. One case each of pityriasis rosea, lichen planus, psoriasis, erythema multiforme, pigmentary purpura, and vasculitis was reported. Most patients had pruritus. Gold-associated eruptions had a median duration of two months, with a range of one week to two years. Most cases resolved promptly with discontinuation of gold or with dose reduction; application of topical steroids was also helpful. (See <a href=\"topic.htm?path=major-side-effects-of-gold-therapy#H20014278\" class=\"medical medical_review\">&quot;Major side effects of gold therapy&quot;, section on 'Mucocutaneous effects'</a>.)</p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h2\">Lithium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cutaneous side effects from <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> therapy have been reported in 3 to 34 percent of patients [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/61\" class=\"abstract_t\">61</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Psoriasis is one of the most common reactions. It may begin for the first time during therapy, or a mild case may be exacerbated when the patient begins the drug.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acne and acneiform eruptions also are common. Pustular lesions may be the result of lysosomal enzyme release and increased neutrophil chemotaxis [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/61\" class=\"abstract_t\">61</a>]. Acneiform lesions may be seen on the forearms and legs in addition to the sites commonly involved in acne vulgaris.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hair loss, especially in women during the first few months of therapy, has frequently been reported.</p><p/><p class=\"headingAnchor\" id=\"H31\"><span class=\"h2\">Halogenoderma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ingestion of halogens such as iodides, bromides, and fluorides can rarely cause cutaneous drug reactions [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/62\" class=\"abstract_t\">62</a>]. Iodides (such as those in seaweed, salt, <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>, and radiocontrast media) can cause acneiform lesions, typically on the face, as well as vesicular, pustular, hemorrhagic, urticarial, fungating, suppurative, nodular, and ulcerative lesions (<a href=\"image.htm?imageKey=DERM%2F108977\" class=\"graphic graphic_picture graphicRef108977 \">picture 18</a>). Swelling of the parotid and submandibular glands has been previously described as iodine mumps. Iododerma due to the administration of intravenous radiocontrast media commonly is seen as an acute eruption; with oral iodine exposure the onset is insidious [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/63\" class=\"abstract_t\">63</a>]. Declining renal function may be a factor in radiocontrast induced iododerma.</p><p><a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">Amiodarone</a> typically induce photosensitivity and a bluish-gray discoloration of the skin (<a href=\"image.htm?imageKey=CARD%2F70419\" class=\"graphic graphic_picture graphicRef70419 \">picture 19</a>). (See <a href=\"topic.htm?path=amiodarone-monitoring-and-management-of-side-effects#H16\" class=\"medical medical_review\">&quot;Amiodarone: Monitoring and management of side effects&quot;, section on 'Skin reactions'</a>.) </p><p>Bromides can cause verrucous ulcerating plaques on the lower extremities [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/62\" class=\"abstract_t\">62</a>]. Discontinuation of the causative agent is sufficient in most patients, with gradual resolution of lesions expected over four to six weeks [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/62\" class=\"abstract_t\">62</a>].</p><p class=\"headingAnchor\" id=\"H4103193943\"><span class=\"h2\">Epidermal growth factor receptor (EGFR) inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Epidermal growth factor receptor (EGFR) inhibitors and other tyrosine kinase inhibitors used to treat cancers are known to cause an inflammatory acneiform eruption involving the face, neck, and upper trunk in the majority of patients receiving these medications (<a href=\"image.htm?imageKey=PC%2F55753\" class=\"graphic graphic_picture graphicRef55753 \">picture 20</a>). (See <a href=\"topic.htm?path=acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors\" class=\"medical medical_review\">&quot;Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h2\">Cytokine therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hematopoietic colony stimulating factors are a heterogeneous group of cytokines that induce proliferation and differentiation of bone marrow precursor cells. They are most frequently administered in the setting of neutropenia secondary to chemotherapy (eg, recombinant human granulocyte or granulocyte-macrophage colony-stimulating factor). Serious cutaneous adverse effects of colony stimulating factors are distinctly rare but include neutrophilic dermatoses and necrotizing vasculitis [<a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/64\" class=\"abstract_t\">64</a>]. Upregulation of neutrophil function and secondary release of cytokines may induce these complications. (See <a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy#H18\" class=\"medical medical_review\">&quot;Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy&quot;, section on 'Cytokine agents'</a>.) </p><p class=\"headingAnchor\" id=\"H83409656\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adverse cutaneous reactions to drugs are common, affecting 2 to 3 percent of hospitalized patients. Drug-induced exanthems, also called morbilliform eruptions, are the most common cutaneous reactions to drugs, responsible for about 75 percent of all drug rashes. The most frequently prescribed medications such as antibiotics and sulfonamides are implicated in most cases. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H3\" class=\"local\">'Drug-induced exanthems'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Less frequently, drugs may cause <span class=\"nowrap\">urticaria/angioedema,</span> anaphylaxis, hypersensitivity vasculitis, and phototoxic and photoallergic reactions. Severe and potentially life-threatening reactions are rare and include exfoliative dermatitis, Stevens-Johnson syndrome, and drug reaction with eosinophilia and systemic symptoms (DRESS). The aromatic antiepileptic agents (<a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, <a href=\"topic.htm?path=oxcarbazepine-drug-information\" class=\"drug drug_general\">oxcarbazepine</a>, and <a href=\"topic.htm?path=phenobarbital-drug-information\" class=\"drug drug_general\">phenobarbital</a>), <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a>, and the sulfonamides are most frequently implicated. (See <a href=\"#H2\" class=\"local\">'Classic drug reaction patterns'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autoimmune bullous diseases (eg, pemphigus, bullous pemphigoid, linear IgA bullous dermatosis) can be rarely induced or triggered by medications, most commonly <a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">penicillamine</a> and other thiol compounds or drugs that are metabolized to thiols (eg, <a href=\"topic.htm?path=captopril-drug-information\" class=\"drug drug_general\">captopril</a>, <a href=\"topic.htm?path=piroxicam-drug-information\" class=\"drug drug_general\">piroxicam</a>). Other rare reactions to drugs include acute generalized pustular eruption (AGEP), lichenoid drug reaction, cutaneous pseudolymphoma, and drug-induced lupus. (See <a href=\"#H15\" class=\"local\">'Uncommon drug eruptions'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/1\" class=\"nounderline abstract_t\">Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/2\" class=\"nounderline abstract_t\">Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765.</a></li><li class=\"breakAll\">Stern RS, Shear NH. Cutaneous reactions to drugs and biological modifiers. In: Cutaneous Medicine and Surgery, Arndt KA, LeBoit PE, Robinson JK, Wintroub BU (Eds), WB Saunders, Philadelphia 1996. Vol 1, p.412.</li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/4\" class=\"nounderline abstract_t\">H&auml;usermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51:297.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/5\" class=\"nounderline abstract_t\">Thyssen JP, Maibach HI. Drug-elicited systemic allergic (contact) dermatitis--update and possible pathomechanisms. Contact Dermatitis 2008; 59:195.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/6\" class=\"nounderline abstract_t\">Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009; 123:434.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/7\" class=\"nounderline abstract_t\">Simons FE, Ardusso LR, Dimov V, et al. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 2013; 162:193.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/8\" class=\"nounderline abstract_t\">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/9\" class=\"nounderline abstract_t\">Loricera J, Blanco R, Ortiz-Sanju&aacute;n F, et al. Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology (Oxford) 2015; 54:77.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/10\" class=\"nounderline abstract_t\">Khetan P, Sethuraman G, Khaitan BK, et al. An aetiological &amp; clinicopathological study on cutaneous vasculitis. Indian J Med Res 2012; 135:107.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/11\" class=\"nounderline abstract_t\">Pendergraft WF 3rd, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 2014; 26:42.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/12\" class=\"nounderline abstract_t\">Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol 1996; 8:34.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/13\" class=\"nounderline abstract_t\">Parker CW. Allergic reactions in man. Pharmacol Rev 1982; 34:85.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/14\" class=\"nounderline abstract_t\">Mullick FG, McAllister HA Jr, Wagner BM, Fenoglio JJ Jr. Drug related vasculitis. Clinicopathologic correlations in 30 patients. Hum Pathol 1979; 10:313.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/15\" class=\"nounderline abstract_t\">Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997; 102:186.</a></li><li class=\"breakAll\">Dermatology in General Medicine, 4th ed, Fitzpatrick TB, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, New York 1993. p.528.</li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/17\" class=\"nounderline abstract_t\">Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138:1019.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/18\" class=\"nounderline abstract_t\">de Frutos C, de Barrio M, Tornero P, et al. Erythema multiforme from sulfaguanidine. Contact Dermatitis 2002; 46:186.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/19\" class=\"nounderline abstract_t\">Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002; 25:965.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/20\" class=\"nounderline abstract_t\">Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15:250.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/21\" class=\"nounderline abstract_t\">Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156:609.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/22\" class=\"nounderline abstract_t\">Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/23\" class=\"nounderline abstract_t\">Cho YT, Lin JW, Chen YC, et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol 2014; 70:539.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/24\" class=\"nounderline abstract_t\">Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 89:542.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/25\" class=\"nounderline abstract_t\">Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998; 37:833.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/26\" class=\"nounderline abstract_t\">Brahimi N, Routier E, Raison-Peyron N, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol 2010; 20:461.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/27\" class=\"nounderline abstract_t\">Gonz&aacute;lez E, Gonz&aacute;lez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996; 35:871.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/28\" class=\"nounderline abstract_t\">Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol 2011; 29:455.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/29\" class=\"nounderline abstract_t\">Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol 1998; 16:393.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/30\" class=\"nounderline abstract_t\">Smith EP, Taylor TB, Meyer LJ, Zone JJ. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol 1993; 29:879.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/31\" class=\"nounderline abstract_t\">Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998; 16:379.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/32\" class=\"nounderline abstract_t\">Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol 2006; 5:562.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/33\" class=\"nounderline abstract_t\">Baz K, Ikizoglu G, Kaya TI, Koca A. Furosemide-induced bullous pemphigoid. J Eur Acad Dermatol Venereol 2002; 16:81.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/34\" class=\"nounderline abstract_t\">Mallet L, Cooper JW, Thomas J. Bullous pemphigoid associated with captopril. DICP 1989; 23:63.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/35\" class=\"nounderline abstract_t\">Wozniak K, Kowalewski C, Hashimoto T, et al. Penicillin-induced anti-p200 pemphigoid: an unusual morphology. Acta Derm Venereol 2006; 86:443.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/36\" class=\"nounderline abstract_t\">Bart BJ, Bean SF. Bullous pemphigoid following the topical use of fluorouracil. Arch Dermatol 1970; 102:457.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/37\" class=\"nounderline abstract_t\">Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131:637.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/38\" class=\"nounderline abstract_t\">Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol 2013; 149:58.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/39\" class=\"nounderline abstract_t\">Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996; 132:272.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/40\" class=\"nounderline abstract_t\">Kuechle MK, Stegemeir E, Maynard B, et al. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol 1994; 30:187.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/41\" class=\"nounderline abstract_t\">Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009; 9:322.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/42\" class=\"nounderline abstract_t\">Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991; 127:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/43\" class=\"nounderline abstract_t\">Momin SB, Del Rosso JQ, Michaels B, Mobini N. Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. Cutis 2009; 83:291.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/44\" class=\"nounderline abstract_t\">Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157:989.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/45\" class=\"nounderline abstract_t\">Thompson DF, Skaehill PA. Drug-induced lichen planus. Pharmacotherapy 1994; 14:561.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/46\" class=\"nounderline abstract_t\">Tosi A, Misciali C, Piraccini BM, et al. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994; 10:310.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/47\" class=\"nounderline abstract_t\">Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg 2000; 19:133.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/48\" class=\"nounderline abstract_t\">Breza TS Jr, Zheng P, Porcu P, Magro CM. Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. J Cutan Pathol 2006; 33:522.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/49\" class=\"nounderline abstract_t\">Jung J, Levin EC, Jarrett R, et al. Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 2011; 147:992.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/50\" class=\"nounderline abstract_t\">Fukamachi S, Sugita K, Sawada Y, et al. Drug-induced CD30+ T cell pseudolymphoma. Eur J Dermatol 2009; 19:292.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/51\" class=\"nounderline abstract_t\">Crowson AN, Magro CM. Antidepressant therapy. A possible cause of atypical cutaneous lymphoid hyperplasia. Arch Dermatol 1995; 131:925.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/52\" class=\"nounderline abstract_t\">Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/53\" class=\"nounderline abstract_t\">Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus 1994; 3:455.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/54\" class=\"nounderline abstract_t\">Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/55\" class=\"nounderline abstract_t\">Broekmans AW, Teepe RG, van der Meer FJ, et al. Protein C (PC) and coumarin-induced skin necrosis. Thromb Res 1986; 41:137.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/56\" class=\"nounderline abstract_t\">Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH. Heparin-induced skin lesions. Lancet 2012; 380:1867.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/57\" class=\"nounderline abstract_t\">Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009; 8:129.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/58\" class=\"nounderline abstract_t\">Menajovsky LB. Heparin-induced thrombocytopenia: clinical manifestations and management strategies. Am J Med 2005; 118 Suppl 8A:21S.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/59\" class=\"nounderline abstract_t\">Handschin AE, Trentz O, Kock HJ, Wanner GA. Low molecular weight heparin-induced skin necrosis-a systematic review. Langenbecks Arch Surg 2005; 390:249.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/60\" class=\"nounderline abstract_t\">Sack U, Kuhn H, Ermann J, et al. Synovial tissue implants from patients with rheumatoid arthritis cause cartilage destruction in knee joints of SCID.bg mice. J Rheumatol 1994; 21:10.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/61\" class=\"nounderline abstract_t\">Gupta AK, Knowles SR, Gupta MA, et al. Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995; 32:382.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/62\" class=\"nounderline abstract_t\">Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management. Am J Clin Dermatol 2003; 4:407.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/63\" class=\"nounderline abstract_t\">Chang MW, Miner JE, Moiin A, Hashimoto K. Iododerma after computed tomographic scan with intravenous radiopaque contrast media. J Am Acad Dermatol 1997; 36:1014.</a></li><li><a href=\"https://www.uptodate.com/contents/drug-eruptions/abstract/64\" class=\"nounderline abstract_t\">Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol 1994; 130:77.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2089 Version 28.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H83409656\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLASSIC DRUG REACTION PATTERNS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Drug-induced exanthems</a><ul><li><a href=\"#H79787039\" id=\"outline-link-H79787039\">- Symmetrical drug-related intertriginous and flexural exanthema</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">Urticaria/angioedema</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Anaphylaxis</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Cutaneous small vessel vasculitis</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Exfoliative dermatitis/erythroderma</a></li><li><a href=\"#H4963591\" id=\"outline-link-H4963591\">Stevens-Johnson syndrome and toxic epidermal necrolysis</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Erythema multiforme</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Fixed drug eruption</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Photosensitivity</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- Phototoxic eruptions</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Photoallergic eruptions</a></li></ul></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">UNCOMMON DRUG ERUPTIONS</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Pemphigus</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Bullous pemphigoid</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Linear IgA bullous dermatosis</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Acute generalized exanthematous pustulosis</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Lichenoid drug eruption (drug-induced lichen planus)</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Alopecia</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Cutaneous pseudolymphoma</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Acral chemotherapy reactions</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Drug-induced lupus</a></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">DRUGS OF SPECIAL CONCERN</a><ul><li><a href=\"#H460534\" id=\"outline-link-H460534\">Anticoagulants</a><ul><li><a href=\"#H460547\" id=\"outline-link-H460547\">- Warfarin</a></li><li><a href=\"#H460596\" id=\"outline-link-H460596\">- Heparin</a></li></ul></li><li><a href=\"#H29\" id=\"outline-link-H29\">Gold</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">Lithium</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">Halogenoderma</a></li><li><a href=\"#H4103193943\" id=\"outline-link-H4103193943\">Epidermal growth factor receptor (EGFR) inhibitors</a></li><li><a href=\"#H32\" id=\"outline-link-H32\">Cytokine therapy</a></li></ul></li><li><a href=\"#H83409656\" id=\"outline-link-H83409656\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/2089|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/54205\" class=\"graphic graphic_picture\">- Morbilliform drug eruption</a></li><li><a href=\"image.htm?imageKey=ALLRG/70062\" class=\"graphic graphic_picture\">- Exanthematous (morbilliform) drug eruption</a></li><li><a href=\"image.htm?imageKey=PC/72519\" class=\"graphic graphic_picture\">- Urticaria 1</a></li><li><a href=\"image.htm?imageKey=DERM/58626\" class=\"graphic graphic_picture\">- Cutaneous small vessel vasculitis - lower leg</a></li><li><a href=\"image.htm?imageKey=DERM/93176\" class=\"graphic graphic_picture\">- Hypersensitivity vasculitis</a></li><li><a href=\"image.htm?imageKey=DERM/93175\" class=\"graphic graphic_picture\">- Drug-induced erythroderma</a></li><li><a href=\"image.htm?imageKey=PC/62321\" class=\"graphic graphic_picture\">- Drug-induced exfoliation</a></li><li><a href=\"image.htm?imageKey=EM/76141\" class=\"graphic graphic_picture\">- Cutaneous findings of Stevens-Johnson syndrome</a></li><li><a href=\"image.htm?imageKey=EM/73805\" class=\"graphic graphic_picture\">- Mucosal changes in Stevens-Johnson syndrome</a></li><li><a href=\"image.htm?imageKey=DERM/59418\" class=\"graphic graphic_picture\">- Toxic epidermal necrolysis - abdomen</a></li><li><a href=\"image.htm?imageKey=DERM/68458\" class=\"graphic graphic_picture\">- Toxic epidermal necrolysis - back</a></li><li><a href=\"image.htm?imageKey=DERM/82150\" class=\"graphic graphic_picture\">- Toxic epidermal necrolysis - bullae</a></li><li><a href=\"image.htm?imageKey=ID/74095\" class=\"graphic graphic_picture\">- Erythema multiforme</a></li><li><a href=\"image.htm?imageKey=DERM/86763\" class=\"graphic graphic_picture\">- DRESS rash 1</a></li><li><a href=\"image.htm?imageKey=DERM/86859\" class=\"graphic graphic_picture\">- Drug reaction with eosinophilia and systemic symptoms 2</a></li><li><a href=\"image.htm?imageKey=DERM/86860\" class=\"graphic graphic_picture\">- Drug reaction with eosinophilia and systemic symptoms 3</a></li><li><a href=\"image.htm?imageKey=DERM/52192\" class=\"graphic graphic_picture\">- Fixed drug eruption arm</a></li><li><a href=\"image.htm?imageKey=DERM/65991\" class=\"graphic graphic_picture\">- Fixed drug eruption penis</a></li><li><a href=\"image.htm?imageKey=DERM/86479\" class=\"graphic graphic_picture\">- Phototoxic eruption</a></li><li><a href=\"image.htm?imageKey=DERM/63557\" class=\"graphic graphic_picture\">- Photoallergic eruption 2</a></li><li><a href=\"image.htm?imageKey=ALLRG/56807\" class=\"graphic graphic_picture\">- Acute generalized exanthematous pustulosis (AGEP)</a></li><li><a href=\"image.htm?imageKey=ALLRG/68610\" class=\"graphic graphic_picture\">- Acute generalized exanthematous pustulosis (AGEP) detail</a></li><li><a href=\"image.htm?imageKey=DERM/63590\" class=\"graphic graphic_picture\">- Lichen planus flexures dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/80165\" class=\"graphic graphic_picture\">- Lichenoid drug eruption</a></li><li><a href=\"image.htm?imageKey=DERM/59258\" class=\"graphic graphic_picture\">- Lichenoid drug eruption hyperpigmentation</a></li><li><a href=\"image.htm?imageKey=DERM/103512\" class=\"graphic graphic_picture\">- Lymphomatoid drug eruption</a></li><li><a href=\"image.htm?imageKey=DERM/79857\" class=\"graphic graphic_picture\">- Acral erythema on the hands</a></li><li><a href=\"image.htm?imageKey=ONC/77501\" class=\"graphic graphic_picture\">- Acral erythema</a></li><li><a href=\"image.htm?imageKey=ONC/81824\" class=\"graphic graphic_picture\">- Sorafenib hand-foot skin reaction</a></li><li><a href=\"image.htm?imageKey=HEME/80462\" class=\"graphic graphic_picture\">- Cutaneous necrosis warfarin</a></li><li><a href=\"image.htm?imageKey=DERM/108977\" class=\"graphic graphic_picture\">- Iododerma</a></li><li><a href=\"image.htm?imageKey=CARD/70419\" class=\"graphic graphic_picture\">- Amiodarone skin pigmentation</a></li><li><a href=\"image.htm?imageKey=PC/55753\" class=\"graphic graphic_picture\">- EGFR inhibitor acneiform erupt</a></li></ul></li><li><div id=\"DERM/2089|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/71375\" class=\"graphic graphic_table\">- Types of allergic reactions</a></li><li><a href=\"image.htm?imageKey=RHEUM/81148\" class=\"graphic graphic_table\">- Drugs cutaneous vasculitis</a></li><li><a href=\"image.htm?imageKey=DERM/86760\" class=\"graphic graphic_table\">- Drugs associated with DRESS</a></li><li><a href=\"image.htm?imageKey=DERM/88293\" class=\"graphic graphic_table\">- Drugs involved in pemphigus</a></li><li><a href=\"image.htm?imageKey=DERM/56085\" class=\"graphic graphic_table\">- Drug causes of pemphigoid</a></li><li><a href=\"image.htm?imageKey=RHEUM/69467\" class=\"graphic graphic_table\">- Features of drug induced LE</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors\" class=\"medical medical_review\">Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-generalized-exanthematous-pustulosis-agep\" class=\"medical medical_review\">Acute generalized exanthematous pustulosis (AGEP)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=amiodarone-monitoring-and-management-of-side-effects\" class=\"medical medical_review\">Amiodarone: Monitoring and management of side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=an-overview-of-angioedema-pathogenesis-and-causes\" class=\"medical medical_review\">An overview of angioedema: Pathogenesis and causes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anaphylaxis-emergency-treatment\" class=\"medical medical_review\">Anaphylaxis: Emergency treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-induced-alopecia\" class=\"medical medical_review\">Chemotherapy-induced alopecia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-heparin-induced-thrombocytopenia\" class=\"medical medical_review\">Clinical presentation and diagnosis of heparin-induced thrombocytopenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-t-cell-pseudolymphomas\" class=\"medical medical_review\">Cutaneous T cell pseudolymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents\" class=\"medical medical_review\">Cutaneous side effects of conventional chemotherapy agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-allergy-classification-and-clinical-features\" class=\"medical medical_review\">Drug allergy: Classification and clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-lupus\" class=\"medical medical_review\">Drug-induced lupus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-bullous-pemphigoid-and-mucous-membrane-pemphigoid\" class=\"medical medical_review\">Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=erythroderma-in-adults\" class=\"medical medical_review\">Erythroderma in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption\" class=\"medical medical_review\">Exanthematous (maculopapular) drug eruption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">Fixed drug eruption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hand-foot-skin-reaction-induced-by-multitargeted-tyrosine-kinase-inhibitors\" class=\"medical medical_review\">Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypersensitivity-reactions-to-clopidogrel\" class=\"medical medical_review\">Hypersensitivity reactions to clopidogrel</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypersensitivity-reactions-to-fluoroquinolones\" class=\"medical medical_review\">Hypersensitivity reactions to fluoroquinolones</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypersensitivity-reactions-to-insulins\" class=\"medical medical_review\">Hypersensitivity reactions to insulins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypersensitivity-reactions-to-macrolides-aminoglycosides-tetracyclines-clindamycin-and-metronidazole\" class=\"medical medical_review\">Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypersensitivity-reactions-to-systemic-glucocorticoids\" class=\"medical medical_review\">Hypersensitivity reactions to systemic glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infusion-reactions-to-systemic-chemotherapy\" class=\"medical medical_review\">Infusion reactions to systemic chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infusion-related-reactions-to-therapeutic-monoclonal-antibodies-used-for-cancer-therapy\" class=\"medical medical_review\">Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lichenoid-drug-eruption-drug-induced-lichen-planus\" class=\"medical medical_review\">Lichenoid drug eruption (drug-induced lichen planus)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=linear-iga-bullous-dermatosis\" class=\"medical medical_review\">Linear IgA bullous dermatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-gold-therapy\" class=\"medical medical_review\">Major side effects of gold therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=new-onset-urticaria\" class=\"medical medical_review\">New-onset urticaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-lichen-planus-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Oral lichen planus: Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-cutaneous-small-vessel-vasculitis\" class=\"medical medical_review\">Overview of cutaneous small vessel vasculitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-erythema-multiforme\" class=\"medical medical_review\">Pathogenesis, clinical features, and diagnosis of erythema multiforme</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=penicillin-allergy-immediate-reactions\" class=\"medical medical_review\">Penicillin allergy: Immediate reactions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=progestogen-hypersensitivity\" class=\"medical medical_review\">Progestogen hypersensitivity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=protein-c-deficiency\" class=\"medical medical_review\">Protein C deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=telogen-effluvium\" class=\"medical medical_review\">Telogen effluvium</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vancomycin-hypersensitivity\" class=\"medical medical_review\">Vancomycin hypersensitivity</a></li></ul></div></div>","javascript":null}